PBYI Q1 2021 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$299M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$98M+91.7% YoY

Gross Profit

$69M69.9% margin

Operating Income

$20M20.5% margin

Net Income

$17M16.8% margin

EPS (Diluted)

$0.40

QoQ Revenue Growth

+86.8%

Cash Flow

Operating Cash Flow

$16M

Free Cash Flow

$16M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$259M

Total Liabilities

$242M

Stockholders' Equity

$16M

Cash & Equivalents

$96M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$98M	$51M	+91.7%
Gross Profit	$69M	$42M	+62.8%
Operating Income	$20M	-$14M	+241.4%
Net Income	$17M	-$17M	+197.6%

Revenue Segments

License

$3M52%

Royalty

$2M48%